Sagar Batra

Mr. Sagar Batra

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 December 2019 in Molecules
Verified
Journal Article
Open access
PDF file
Taj MohammadTaj Mohammad
Taj Mohammad
SBSagar Batra
Sagar Batra
RDRashmi Dahiya
Rashmi Dahiya
MBMohammad Hassan Baig
Mohammad Hassan Baig
Irfan A. RatherIrfan A. Rather
Irfan A. Rather
Md. Imtaiyaz HassanMd. Imtaiyaz Hassan
Md. Imtaiyaz Hassan
Cyclin-dependent kinase 2 (CDK2) is an essential protein kinase involved in the cell cycle regulation. The abnormal activity of CDK2 is associated with cancer progression and metastasis. Here, we have performed structure-based virtual screening of the PubChem database to identify potent CDK2 inhibitors. First, we retrieved all compounds from the PubChem database having at least 90% structural similarity with the known CDK2 inhibitors. The selected compounds were subjected to structure-based molecular docking studies to investigate their pattern of interaction and estimate their binding affinities with CDK2. Selected compounds were further filtered out based on their physicochemical and ADMET properties. Detailed interaction analysis revealed that selected compounds interact with the functionally important residues of the active site pocket of CDK2. All-atom molecular dynamics simulation was performed to evaluate conformational changes, stability and the interaction mechanism of CDK2 in-complex with the selected compound. We found that binding of 6-N,6-N-dimethyl-9-(2-phenylethyl)purine-2,6-diamine stabilizes the structure of CDK2 and causes minimal conformational change. Finally, we suggest that the compound (PubChem ID 101874157) would be a promising scaffold to be further exploited as a potential inhibitor of CDK2 for therapeutic management of cancer after required validation.

22 October 2021 in PLOS ONE
Verified
Journal Article
Open access
PDF file
ASAlaa Shafie
Alaa Shafie
SKShama Khan
Shama Khan
SBSagar Batra
Sagar Batra
Farah AnjumFarah Anjum
Farah Anjum
Taj MohammadTaj Mohammad
Taj Mohammad
Md. Imtaiyaz HassanMd. Imtaiyaz Hassan
Md. Imtaiyaz Hassan
PIM1, is a serine/threonine proto-oncogene kinase, involved in many biological functions, including cell survival, proliferation, and differentiation, thus play a key role in oncogenesis. It plays a crucial role in the onset and progression of various hematopoietic and non-hematopoietic malignancies, including acute myeloid leukemia and prostate cancer. Mutations in PIM1, especially in its kinase domain, can induce abnormal structural changes and thus alter functionalities that can lead to disease progression and other complexities. Herein, we have performed an extensive analysis of the PIM1 mutations at sequence and structure level while utilizing state-of-the-art computational approaches. Based on the impact on PIM1, numerous pathogenic and destabilizing mutations were identified and subsequently analyzed in detail. Finally, two amino acid substitutions (W109C and F147C) in the kinase domain of PIM1 were selected to explore their impact on the PIM1 structure in a time evolution manner using all-atom molecular dynamics (MD) simulations for 200 ns. MD results indicate significant conformational altercations in the structure of PIM1, especially upon F147C mutation. This study provides a significant insight into the PIM1 dysfunction upon single amino acid substitutions, which can be utilized to get insights into the molecular basis of PIM1-associated disease progression.

3 January 2021 in Journal of Molecular Recognition
Verified
Journal Article
Closed access
PDF file
SBSagar Batra
Sagar Batra
PPPuranjaya Pancholi
Puranjaya Pancholi
MRMrinalini Roy
Mrinalini Roy
SKSanket Kaushik
Sanket Kaushik
AJAnupam Jyoti
Anupam Jyoti
VSVijay Kumar Srivastava
Vijay Kumar Srivastava

1 January 2020 in Pharmacognosy Magazine
Verified
Journal Article
Closed access
SKSanket Kaushik
Sanket Kaushik
HSHarpreet Singh
Harpreet Singh
SDSatyajeet Das
Satyajeet Das
Pramodkumar P GuptaPramodkumar P Gupta
Pramodkumar P Gupta
SBSagar Batra
Sagar Batra
Shanker Lal KothariShanker Lal Kothari
Shanker Lal Kothari

28 March 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
SBSagar Batra
Sagar Batra
FOFrancisco Olmo
Francisco Olmo
TRTimothy J Ragan
Timothy J Ragan
MKMerve Kaplan
Merve Kaplan
VCValeria Calvaresi
Valeria Calvaresi
ICIvan Campeotto
Ivan Campeotto
Chagas disease, caused by the protozoan parasite Trypanosoma cruzi , remains a significant global public health concern. Despite its profound health impact in both endemic and non-endemic areas, no vaccine is available, and the existing therapies are outdated, producing severe side effects. The 80kDa prolyl oligopeptidase of Trypanosoma cruzi (TcPOP) has been recently identified as a leading candidate for Chagas vaccine development. We report the first three-dimensional structure of TcPOP in open and closed conformation, at a global resolution of 3.8 and 3.6 Å respectively, determined using single-particle cryo-electron microscopy. Multiple conformations were observed and further characterized using plasmonic optical tweezers and hydrogen-deuterium exchange mass spectrometry. To assess the immunogenic potential of TcPOP, we immunized mice and evaluated both polyclonal and monoclonal responses against the TcPOP antigen and its homologues. The results revealed invasion blocking properties of anti-TcPOP polyclonal response via parasite lysis and its cross-reactivity versus closely-related POPs but not with human homologues. We were also able to produce and characterise three monoclonal antibodies, one of which showed neutralising properties and inhibition of parasite invasion via non-lytic mechanism. Collectively, our findings provide critical structural and functional insights necessary to understand the immunogenicity of TcPOP for future Chagas vaccine development and diagnostic applications.